Discriminative stimulus: Effects of l-α-acetylmethadol (LAAM), buprenorphine and methadone in morphine-treated rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 2, 1997, Pages 574-584

  Brandt, Michael R ^a   Cabansag, Sharon R ^a   France, Charles P ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DINORDIMEPHEPTANOL ACETATE; DRUG METABOLITE; LEVACETYLMETHADOL; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; NARCOTIC ANTAGONIST; NORACYMETHADOL; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DEPENDENCE TREATMENT; FEMALE; MALE; METHADONE TREATMENT; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RHESUS MONKEY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BUPRENORPHINE; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MACACA MULATTA; MALE; METHADONE; METHADYL ACETATE; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS;

EID: 0030746309     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. ACETO, M. D., BOWMAN, E. R., HARRIS, L. S. AND MAY, E. L.: Dependence studies of new compounds in the rhesus monkey and mouse. In Proceedings, The Committee on Problems of Drug Dependence, National Institute on Drug Abuse Research Monograph 119, ed by L. S. Harris, pp. 513-558, U.S. Govt. Printing Office, Washington, DC, 1992.
2. 2 analysis. J. Pharmacol. Exp. Ther. 243: 591-597, 1987.
3. BERTALMIO, A. J., MEDZIHRADSKY, F., WINGER, G. AND WOODS, J. H.: Differential influence of N-dealkylation on the stimulus properties of some opioid agonists. J. Pharmacol. Exp. Ther. 261: 278-284, 1992.
4. BICKEL, W. K. ANU AMASS, L.: Buprenorphine treatment of opioid dependence: A review. Exp. Clin. Psychopharmacol. 3: 477-489, 1995.
5. BICKEL, W. K., STITZER, M. L., BIGELOW, G. E., LIEBSON, I. A., JASINSKI, D. R. AND JOHNSON, R. E.: Buprenorphine: Dose-related blockade of opioid challenge effects in opioid dependent humans. J. Pharmacol. Exp. Ther. 247: 47-53, 1988.
6. BILLINGS, R. E., MCMAHON, R. E. AND BLAKE, D. A.: 1-Acetylmethadol (LAM) treatment of opiate dependence: Plasma and urine levels of two pharmacologically active metabolites. Life Sci. 14: 1437-1446, 1974.
7. 2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr 2033 in rhesus monkeys. J. Pharmacol. Exp. Ther. 264: 145-151, 1993.
8. CARROLL, J. A., SHAW, J. S. AND WICKENDEN, A. D.: The physiological relevance of low agonist affinity binding at opioid μ-receptors. Br. J. Pharmacol. 94: 625-631, 1988.
9. COMER, S. D., MCNUTT, R. W., CHANG, K.-J., DE COSTA, B. R., MOSBERG, H. I. AND WOODS, J. H.: Discriminative stimulus effects of BW373U86: A nonpeptide ligand with selectivity for delta opioid receptors. J. Pharmacol. Exp. Ther. 267: 866-874, 1993.
10. CRAFT, R. M. AND DYKSTRA, L. A.: Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output. J. Pharmacol. Exp. Ther. 260: 327-333, 1992.
11. CROWLEY, T. J., MACDONALD, M. J. AND ZERBE, G.: Variability in simian motor and social behavior with alternating-day acetylmethadol. Psychopharmacology 85: 353-360, 1985.
12. DOWNS, D. A.: Interactions of acetylmethadol or methadone with other drugs in rhesus monkeys. Pharmacol. Biochem. Behav. 10: 407-414, 1979.
13. DOWNS, D. A., THOMAS, D. J. AND BRAUDE, M. C.: Chronic effects of acetylmethadol and methadone in rhesus monkeys. Life Sci. 21: 719-726, 1977.
14. EMMETT-OGLESBY, M. W., MATHIS, D. A., MOON, R. T. Y. AND LAL, H.: Animal models of drug withdrawal symptoms. Psychopharmacology 101: 292-309, 1990.
15. FINKLE, B. S., JENNISON, T. A., CHINN, D. M., LING, W. AND HOLMES, E. D.: Plasma and urine disposition of 1-α-acetylmethadol and its principal metabolites in man. J. Anal. Toxicol. 6: 100-105, 1982.
16. FRANCE, C. P.: Drug discrimination as a model for studying opioid dependence and withdrawal in animals. In Strategies for Studying Brain Disorders, ed. by T. Palomo and T. Archer, vol. 1, pp. 281-301, Farrand Press, London, 1994.
17. FRANCE, C. P. AND MORSE, W. H.: Pharmacological characterization of super-sensitivity to naltrexone in squirrel monkeys (Abstract). Pharmacol. Biochem. Behav. 25: 307, 1986.
18. FRANCE, C. P. AND WOODS, J. H.: Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J. Pharmacol. Exp. Ther. 250: 937-943, 1989.
19. FRANCE, C. P., JACOBSON, A. E. AND WOODS, J. H.: Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine. J. Pharmacol. Exp. Ther. 230: 652-657, 1984.
20. FRANCE, C. P., DECOSTA, B. R., JACOBSON, A. E., RICE, K. C. AND WOODS, J. H.: Apparent, affinity of opioid antagonists in morphine-treated rhesus monkeys discriminating between saline and naltrexone. J. Pharmacol. Exp. Ther. 252: 600-604, 1990.
21. FUKASE, H., FUKUZAKI, K., KOJA, T., NAGATA, R. AND LUKAS, S. E.: Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys. Psychopharmacology 116: 396-400, 1994.
22. GERAK, L. R. AND FRANCE, C. P.: Discriminative stimulus effects of nalbuphine in rhesus monkeys. J. Pharmacol. Exp. Ther. 276: 523-531, 1996.
23. GERAK, L. R., BUTELMAN, E. R., WOODS, J. H. AND FRANCE, C. P.: Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. J. Pharmacol. Exp. Ther. 271: 993-999, 1994.
24. GMEREK, D. E.: The suppression of deprivation and antagonist-induced withdrawal in morphine-dependent rhesus monkeys. Neuropeptides 5: 19-22, 1984.
25. HAMBROOK, J. M. AND RANCE, M. J.: The interaction of buprenorphine with the opiate receptor: Lipophilicity as a determining factor in drug-receptor kinetics. In Opiates and Endogenous Opioid Peptides, ed by H. Kosterlitz, pp 295-301, Elsevier/North-Holland, Amsterdam, 1976.
26. HARRIGAN, S. E. AND DOWNS, D. A.: Self-administration of heroin, acetylmethadol, morphine, and methadone in rhesus monkeys. Life Sci. 22: 619-624, 1978.
27. HENDERSON, G. L., WILSON, B. K. AND LAU, D. H. M.: Plasma l-α-acetylmethadol (LAAM) after acute and chronic administration. Clin. Pharmacol. Ther. 21: 16-25, 1976.
28. HENDERSON, G. L., WEINBERG, J. A., HARGREAVES, W. A., LAU, D. H. M., TYLER, J. AND BAKER, B.: Accumulation of 1-α-acetylmethadol [LAAM] and active metabolites in plasma following chronic administration. J. Anal. Toxicol. 1: 1-5, 1977.
29. HOLTZMAN, S. G.: Discriminative stimulus properties of levo-alpha-acetylmethadol and its metabolites. Pharmacol. Biochem. Behav. 10: 565-568, 1979.
30. HOLTZMAN, S. G.: Discriminative stimulus effects of morphine withdrawal in the dependent rat: Suppression by opiate and nonopiate drugs. J. Pharmacol. Exp. Ther. 233: 80-86, 1985.
31. HOLTZMAN, S. G.: Discriminative stimulus effects of drugs: Relationship to potential for abuse. In Testing and Evaluation of Drugs of Abuse, ed. by M. W. Adler and A. Cowan, pp.193-210, Wiley-Liss, Inc., New York, 1990.
32. JASINSKI, D. R., PEVNICK, J. S. AND GRIFFITH, J. D.: Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry 35: 501-516, 1978.
33. KAIKO, R. F. AND INTURRISI, C. E.: Disposition of acetylmethadol in relation to pharmacologic action. Clin. Pharmacol. Ther. 18: 96-103, 1975.
34. KENAKIN, T.: Pharmacological Analysis of Drug-Receptor Interaction, 2nd ed., Raven Press, New York, 1993.
35. KREEK, M. J.: Rationale for maintenance pharmacotherapy of opiate dependence. In Addictive States, ed by C. P. O'Brien and J. H. Jaffe, pp. 205-230, Raven Press, Ltd., New York, 1992.
36. LEVINE, R., ZAKS, A., FINK, M. AND FREEDMAN, A. M.: Levomethadyl acetate; prolonged duration of opioid effects, including cross tolerance to heroin, in man. JAMA 226: 316-318, 1973.
37. LIGUORI, A., MORSE, W. H. AND BERGMAN, J.: Respiratory effects of opioid full and partial agonists in rhesus monkeys. J. Pharmacol. Exp. Ther. 277: 462-472, 1996.
38. LING, W., RAWSON, R. A. AND COMPTON, M. A.: Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine. J. Psychoactive Drugs 26: 119-128, 1994.
39. LUKAS, S. E., GRIFFITHS, R. R. AND BRADY, J. V.: Buprenorphine self-administration by the baboon: Comparison with other opioids. In Proceedings, The Committee on Problems of Drug Dependence, National Institute on Drug Abuse Research Monograph 43, ed by L. S. Harris, pp. 178-183, U.S. Goverment Printing Office, Washington, DC, 1983.
40. MCGIVNEY, W. T. AND MCMILLAN, D. E.: The effects of levo-α-acetylmethadol and its metabolites on schedule-controlled behavior in the pigeon. J. Pharmacol. Exp. Ther. 216: 299-305, 1981.
41. MELLO, N. K., BREE, M. P. AND MENDELSON, J. H.: Buprenorphine self-administration by rhesus monkeys. Pharmacol. Biochem. Behav. 15: 215-225, 1981.
42. 3H]acetylmethadol (LAAM) in the monkey: evidence for a new metabolite. J. Pharm. Pharmacol. 28: 316-318, 1976.
43. 2]-acetylnormethadol (nor-LAAM), the active metabolite of LAAM, in acutely and chronically treated rhesus monkeys. J. Pharmacol. Exp. Ther. 214: 599-607, 1980.
44. MOERSCHBAECHER, J. M., THOMPSON, D. M. AND WINSAUER, P. J.: Effects of heroin, methadone, LAAM and cyclazocine on acquisition and performance of response sequences in monkeys. Pharmacol. Biochem. Behav. 19: 701-710, 1983.
45. MULE, S. J. AND MISRA, A. L.: Pharmacology of 1-α-acetylmethadol (LAAM) in subhuman primates. Ann. N.Y. Acad. Sci. 311: 199-213, 1978.
46. NEGUS, S. S., PICKER, M. J. AND DYKSTRA, L. A.: Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats. Psychopharmacology 98: 141-143, 1989.
47. NEGUS, S. S., BURKE, T. F., MEDZIHRADSKY, F. AND WOODS, J. H.: Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: Antagonism by quadazocine. J. Pharmacol. Exp. Ther. 267: 896-903, 1993.
48. NEIL, A.: Affinities of some common opioid analgesics towards four binding sites in mouse brain. Naunyn-Schmiedeberg Arch Pharmacol 328: 24-29, 1984.
49. NICKANDER, R., BOOHER, R. AND MILES, H.: α-1-acetylmethadol and its N-demethylated metabolites have potent opiate action in the guinea pig isolated ileum. Life Sci. 14: 2011-2017, 1974.
50. PRESTON, K. L. AND BIGELOW, G. E.: Subjective and discriminative effects of drugs. Behav. Pharmacol. 2: 293-313, 1991.
51. RENAULT, P. F.: Treatment of heroin-dependent persons with antagonists Current status. In Narcotic Antagonists: Naltrexone Pharmacochemistry and Sustained-Release Preparations, National Institute of Drug Abuse Research Monograph 28, ed. by R. E. Willette and G. Barnett, pp. 11-21, U.S. Government Printing Office, Washington, DC, 1981.
52. RICHARDS, M. L. AND SADEE, W.: In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method. Eur. J. Pharmacol. 114: 343-353, 1985.
53. ROSEN, M. I., WALLACE, E. A., MCMAHON, T. J., PEARSALL, H. R., WOODS, S. W., PRICE, L. H. AND KOSTEN, T. R.: Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend. 35: 141-149, 1994.
54. SADEE, W., ROSENBAUM, J. S. AND HERZ, A.: Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J. Pharmacol. Exp. Ther. 223: 157-162, 1982.
55. SCHAEFER, G. J. AND HOLTZMAN, S. G.: Discriminative effects of morphine in the squirrel monkey. J. Pharmacol. Exp. Ther. 201: 67-75, 1977.
56. SHANNON, H. E., CONE, E. J. AND GORODETZKY, C. W.: Morphine-like discriminative stimulus effects of buprenorphine and demethoxybuprenorphine in rats: Quantitative antagonism by naloxone. J. Pharmacol. Exp. Ther. 229: 768-774, 1984.
57. TAYLOR, C. W.: The role of G proteins in transmembrane signalling. Biochem. J. 272: 1-13, 1990.
58. 2 and receptor differentiation: A statistical analysis of competitive antagonism. Life Sci. 25: 637-654, 1979.
59. TEAL, J. J. AND HOLTZMAN, S. G.: Stereoselectivity of the stimulus effects of morphine and cyclazocine in the squirrel monkey. J. Pharmacol. Exp. Ther. 215: 369-376, 1980.
60. VALENTINO, R. J., HERLING, S. AND WOODS, J. H.: Discriminative stimulus effects of naltrexone in narcotic-naive and morphine-treated pigeons. J. Pharmacol. Exp. Ther. 224: 307-313, 1983.
61. WALKER, E. A., ZERNING, G. AND WOODS, J. H.: Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J. Pharmacol. Exp. Ther. 273: 1345-1352, 1995.
62. WALSH, S. L., PRESTON, K. L., BIGELOW, G. E. AND STITZER, M. L.: Acute administration of buprenorphine in humans: Partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274: 361-372, 1995.
63. WALSH, S. L., PRESTON, K. L., STITZER, M. L., CONE, E. J. AND BIGELOW, G. E.: Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clin. Pharmacol. Ther. 55: 569-580, 1994.
64. WEISSMAN, A.: The discriminability of naloxone in rats depends on concomitant morphine treatment. In Stimulus Properties of Drugs: Ten Years of Progress, ed. by F. C. Colpaert and J. A. Rosecrans, pp. 209-214, Elsevier/ North-Holland Biomedical Press, Amsterdam, 1978.
65. WINGER, G., SKJOLDAGER, P. AND WOODS, J. H.: Effects of buprenorphine and other opioid agonists and antagonists on alfentanil-and cocaine-reinforced responding in rhesus monkeys. J. Pharmacol. Exp. Ther. 261: 311-317, 1992.
66. WOODS, J. H., FRANCE, C. P. AND WINGER, G. D.: Behavioral pharmacology of buprenorphine: Issues relevant to its potential in treating drug abuse. In Buprenorphine: An Alternative Treatment for Opioid Dependence, National Institute on Drug Abuse Research Monograph 121, ed. by J. D. Blaine, pp 12-27, U.S. Government Printing Office, Washington, DC. 1992.
67. YOUNG, A. M., KAPITSOPOULOS, G. AND MAKHAY, M. M.: Tolerance to morphine-like stimulus effects of mu opioid agonists. J. Pharmacol. Exp. Ther. 257: 795-805, 1991.
68. YOUNG, A. M., STEPHENS, K. R., HEIN, D. W. AND WOODS, J. H.: Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. J. Pharmacol. Exp. Ther. 229: 118-126, 1984.
69. YOUNG, G. A., STEINFELS, G. F. AND KHAZAN, N.: Transitional patterns of self-administration following substitution of methadone or 1-alpha-acetylmethadol (LAAM) for morphine in dependent rats. Drug Alcohol Dependence 3: 273-279, 1978.
70. YOUNG, G. A., STEINFELS, G. F. AND KHAZAN, N.: Pharmacodynamic profiles of 1-α-acetylmethadol (LAAM) and its N-demethylated metabolites, nor-LAAM and dinor-LAAM, during self-administration in the dependent rat. J. Pharmacol. Exp. Ther. 210: 453-457, 1979.